This property of CORTROSYN™ assumes added importance in view of the known antigenicity of natural ACTH.ĬORTROSYN™ (cosyntropin) for Injection is intended for use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.
#Cosyntropin atc4 full#
Those containing 1–26, 1–24 or 1–23 amino acids have very little immunologic although full biologic activity. In contrast, synthetic polypeptides containing 1–19 or fewer amino acids have no detectable immunologic activity. This activity resides in the C-terminal portion of the molecule and the 22–39 amino acid residues exhibit the greatest degree of antigenicity. Animal, human and synthetic ACTH (1–39) which all contain 39 amino acids exhibit similar immunologic activity. These are considered to be without physiological or clinical significance. The extra-adrenal effects which natural ACTH and CORTROSYN™ have in common include increased melanotropic activity, increased growth hormone secretion and an adipokinetic effect. This dose of CORTROSYN™ will produce maximal secretion of 17-OH corticosteroids, 17- ketosteroids and / or 17 - ketogenic steroids. It has been established that 0.25 mg of CORTROSYN™ will stimulate the adrenal cortex maximally and to the same extent as 25 units of natural ACTH. The pharmacologic profile of CORTROSYN™ is similar to that of purified natural ACTH. For example, the decrement from 20 to 19 results in a 70% loss of potency. Partial or complete loss of activity is noted with progressive shortening of the chain beyond 20 amino acid residues. Various studies have shown that the biologic activity of ACTH resides in the N-terminal portion of the molecule and that the 1 – 20 amino acid residue is the minimal sequence retaining full activity. CORTROSYN™ (cosyntropin) for Injection exhibits the full corticosteroidogenic activity of natural ACTH.